FINWIRES · TerminalFinancial News · Live TerminalLIVE

HKG:1276

19 stories mentioning HKG:1276Updated 1d ago

Every FINWIRES story that references HKG:1276, newest first.

Hengrui Pharma Wins China Regulator's Nod for Three Drugs

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) has received market approval from China's National Medical Products Administration (NMPA) for its insulin sudelidec injection, according to a Wednesday filing to the Hong Kong stock exchange.The company independently developed the Class 1 therapeutic biological product for treating adults with type 2 diabetes mellitus, with approvals granted for 3ml:300 units in both pre-filled injection pen and cartridge formats.Additionally, the pharmaceutical firm secured regulatory acceptance for its drug marketing authorization application for Ruikang Luzetutamab for Injection (SHR-A2009), intended for adult patients with lung cancer that has progressed after epidermal growth factor receptor tyrosine kinase inhibitor therapy.In a separate filing, Hengrui announced that its subsidiary, Fujian Shengdi Medicine, received NMPA approval to initiate a Phase II clinical trial for HRS5580 for Injection, a selective neurokinin-1 receptor antagonist designed to prevent postoperative nausea and vomiting.

HKG:1276SHA:600276

Hengrui Pharmaceuticals Gets China Nod for Five Cancer Drug Trials

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) subsidiaries obtained China's regulatory approval to conduct clinical trials for five anticancer drugs.These drugs are SHR-4610, SHR-1826, SHR-A2009, Ruikang Trastuzumab and SHR-8068, according to a Monday filing with the Shanghai bourse.Shares of the company slid 1% on the Shanghai bourse and rose 1% in Hong Kong.

HKG:1276SHA:600276

Jiangsu Hengrui Pharmaceuticals Gets China Nod for Hypertension Drug Trial

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) subsidiary Shandong Shengdi obtained China's regulatory approval to conduct Phase II/III clinical trials for HRS-1780 tablets.The tablets are used for uncontrolled or resistant hypertension, according to a Monday filing with the Shanghai bourse.

HKG:1276SHA:600276

Hengrui Pharmaceuticals' Pancreatic Cancer Drug Gets US FDA Orphan Status

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) said its SHR-4375 Injection has received orphan drug designation from the U.S. Food and Drug Administration for treating pancreatic cancer.The designation will provide the company with opportunities to receive U.S. policy support in the areas of product development, registration and commercialization, according to a Monday filing with the Shanghai bourse.

HKG:1276SHA:600276

Nomura Adjusts Jiangsu Hengrui Pharmaceuticals' Price Target to HK$82.18 From HK$87.49, Keeps at Buy

Jiangsu Hengrui Pharmaceuticals (HKG:1276) has an average rating of overweight and mean price target of HK$81.15, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

Hengrui Pharmaceuticals Gets Marketing Approval for Cervical Cancer Combo Treatment

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) said China's drug regulator approved the marketing of camrelizumab in combination with famitinib malate for the first-line treatment of patients with recurrent or metastatic cervical cancer.This approval marks the official upgrade of the combination therapy to first-line treatment from second-line for advanced cervical cancer, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company were down 1% in recent trade.

HKG:1276SHA:600276

Hengrui Pharma Gets China Clinical Trial Nod for Osteoarthritis Injection; Shares Fall 4%

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) received Phase 3 clinical trial approval from China's National Medical Products Administration for its HRS9531 injection, according to a Friday filing with the Shanghai bourse.Hengrui will initiate trials for the drug in obese adult patients with knee osteoarthritis.The HRS9531 injection targets the gastric inhibitory peptide receptor and glucagon-like peptide-1 receptor. It has been previously tested on type 2 diabetes, obesity with heart failure, sleep apnea, and polycystic ovary syndrome.The company's cumulative investment in the drug reached 700.8 million yuan.Shares fell 4% in Hong Kong and Shanghai during morning trading on Friday.

HKG:1276SHA:600276

Hengrui Pharma Wins China Nod for Stroke Drug Clinical Trial

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) unit Beijing Shengdi Pharmaceutical obtained clinical trial approval from China's National Medical Products Administration for its HRS-8829 injection concentrate, according to a Thursday filing on the Shanghai bourse.The clinical trials will evaluate the drug's use for the treatment of acute ischemic stroke.The Hengrui unit has so far invested 16.6 million yuan in the drug's research and development.The pharmaceutical company's shares slipped over 2% in Shanghai trade recently.

HKG:1276SHA:600276

Hengrui Pharmaceuticals Gets Nod for Atopic Dermatitis Drug Testing

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) received approval from China's National Medical Products Administration for the clinical trial of HRS-8797 tablets, according to a Thursday disclosure on the Shanghai bourse.The drug will be tested as a treatment for atopic dermatitis.The pharmaceutical company's shares slipped 1% during the morning trade.

HKG:1276SHA:600276

Hengrui Pharmaceuticals Gets China Nod For Lupus, Arthritis Drug Trials

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) has secured clearance from China's drug regulator to begin clinical trials for its SHR-3079 injection to treat adult systemic lupus erythematosus and adult rheumatoid arthritis.There are currently no similar drugs approved for marketing globally, the company said in a Shanghai bourse filing on Tuesday.The drug is also already in Phase I trials for B-cell non-Hodgkin's lymphoma.Hengrui has invested about 24.4 million yuan in the project to date.

HKG:1276SHA:600276

Hengrui Pharma Gets Nod to Trial Drug Combination for Hepatocellular Carcinoma

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276), through its subsidiaries, received approval from China's National Medical Products Administration for the clinical trials of a drug combination for the treatment of hepatocellular carcinoma, according to a Shanghai bourse filing on Friday.The pharmaceutical company was given the green light to trial SHR-8068 injection in combination with adebelimab injection, and apatinib mesylate tablets.Adebelimab injection was already approved as a lung cancer treatment, while apatinib mesylate tablets was approved as a treatment for various cancers, including gastric, hepatocellular and breast cancer.The company's Hong Kong shares rose 2% and Shanghai shares increased 1% during the morning trade.

HKG:1276SHA:600276

Hengrui Pharma Gets Nod to Trial HRS-4508 Tablets As Advanced Tumor Treatment; Shares Down 4%

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) received approval from China's National Medical Products Administration to conduct clinical trials on HRS-4508 tablets, according to a Shanghai bourse filing on Friday.The drug will be tested as a treatment for advanced solid tumors.The pharmaceutical company invested 81.8 million yuan into the research and development of the drug.The company's Hong Kong shares dropped 4%, while Shanghai shares slipped 1% during the morning trade.

HKG:1276SHA:600276

Hengrui Pharmaceuticals Unit Wins China Approval to Expand Indication of Cancer Drug

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) said a unit received China's National Medical Products Administration approval to expand the indication of adebrelimab, according to a Thursday Hong Kong bourse filing.The drug can now be used as neoadjuvant therapy in non-small cell lung cancer. It was previously approved as a first-line treatment of extensive-stage small cell lung cancer.

HKG:1276SHA:600276

Hengrui Pharmaceuticals Unit Wins China Marketing Approval for Dry Eye Drug

Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) said a unit received marketing approval from China's National Medical Products Administration for Cyclosporine Ophthalmic Solution (IV), marketed as CyclASol, according to a Thursday Hong Kong bourse filing.CyclASol is indicated to promote tear secretion and improve the signs and symptoms of dry eye disease in patients with reduced tear production.

HKG:1276SHA:600276

European Drug Regulator Accepts Hengrui Pharma's Marketing Application for Revulutamide Tablets

The European Medicines Agency accepted Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) marketing application for revulutamide tablets, according to a Shanghai bourse filing on Tuesday.The drug is used in combination with androgen deprivation therapy for the treatment of adult male patients with prostate cancer.The Chinese pharmaceutical company's shares rose 2% during the morning trade.

HKG:1276SHA:600276

China Greenlights Clinical Trials for Two Hengrui Pharma Drugs, Approves Another Indication for Breast Cancer Drug

China's drug regulator approved clinical trials for Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) SHR-6914 injection and HRS-7525 tablets, according to separate filings with the Shanghai bourse on Wednesday.The SHR-6914 injection, produced by subsidiary Suzhou Shengdiya Biopharmaceutical, is indicated for tumors related to prostate cancer.Hengrui's HRS-7525 tablets are indicated for solid tumors.The regulator also approved another indication for its dalpiciclib isethionate tablets for early-stage breast cancer with high risk of recurrence, and are hormone receptor-positive and human epidermal growth factor receptor 2-negative.

HKG:1276SHA:600276

Hong Kong Stocks End Lower as U.S.-Iran Talks Remain Stalled; Hengrui Pharma Jumps

Hong Kong stocks ended slightly lower on Tuesday as fading expectations for progress in U.S.-Iran negotiations and caution ahead of U.S. inflation data weighed on sentiment.The Hang Seng Index shed 0.2%, or 58.93 points, to close at 26,347.91, while the Hang Seng China Enterprises Index barely moved in negative territory to finish at 8,882.37.U.S. President Donald Trump said on Monday that a ceasefire with Iran was "on life support" after Tehran's response to a U.S. proposal highlighted divisions between the two sides.Tehran has called for compensation for war-related damage, an end to the U.S. naval blockade, assurances against further attacks, and the resumption of Iranian oil exports.Markets are also closely watching Trump's visit to China, which begins on Wednesday.In corporate news, Hengrui Pharmaceuticals (HKG:1276, SHA:600276) advanced nearly 5% in Hong Kong after signing a drug development deal with Bristol Myers Squibb worth up to $15.2 billion.

Hang SengHKG:1276SHA:600276

Jiangsu Hengrui Pharma Signs $15 Billion Drug Development Deal with Bristol Myers Squibb

Jiangsu Hengrui Pharmaceuticals (HKG:1276, SHA:600276) entered into global collaboration and license agreements with Bristol Myers Squibb to develop 13 early-stage programs across oncology, hematology, and immunology, according to a Tuesday Hong Kong bourse filing.The agreements include four oncology and hematology programs from Hengrui, four immunology programs from Bristol Myers Squibb, and five jointly discovered and developed programs.The U.S.-headquartered biopharma company will pay Hengrui up to $950 million, including a $600 million upfront payment, a $175 million first anniversary payment, and a contingent $175 million payment in 2028.The potential total value of the agreements could reach about $15.2 billion, including milestone payments tied to development, regulatory, and commercial targets.Under the deal, Bristol Myers will obtain exclusive worldwide rights to Hengrui-originated programs outside mainland China, Hong Kong, and Macau, while Hengrui will secure exclusive rights to Bristol Myers Squibb-originated programs within those markets.The companies expect the agreements to close in the third quarter, subject to antitrust review and other customary closing conditions.

HKG:1276SHA:600276

Hengrui Pharma's Q1 Profit Climbs 22%

Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) recorded a 22% rise in attributable profit for the first quarter of 2026 to 2.28 billion yuan from 1.87 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.Earnings per share jumped to 0.34 yuan from 0.30 yuan in the corresponding period of the previous fiscal year.Operating revenue climbed 13% to 8.14 billion yuan from 7.21 billion yuan in the year-ago period.

HKG:1276SHA:600276

Track with the FINWIRES app suite

Track HKG:1276 in your portfolio

Analyze HKG:1276 options with the wheel strategy

See market sentiment on HKG:1276